Identifying connections among genetic diseases can accelerate the development of new therapies. If this potential is to be realized, argues Sharon F. Terry, research funding must no longer be focused on individual diseases.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$189.00 per year
only $15.75 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Whalen, J. FDA approves a novel Novartis drug. Wall Street Journal B1 (19 Jun 2009).
Collins, F. S. Unprecedented therapeutic opportunities for rare and neglected diseases. 2009 Genetic Alliance Annual Conference [online], (2009).
Lachmann, H. J. et al. Use of canakinumab in the cryopyrin-associated periodic syndrome. N. Engl. J. Med. 360, 2416–2425 (2009).
McDermott, M. F. Rilonacept in the treatment of chronic inflammatory disorders. Drugs Today 45, 423–430 (2009).
Matt, P. et al. Recent advances in understanding Marfan syndrome: should we now treat surgical patients with losartan? J. Thorac. Cardiovasc. Surg. 135, 389–394 (2008).
[No authors listed.] Is inflammation the root of all disease? UC Berkeley Wellness Letter [online], (2008).
Balkwill, F. & Mantovani A. Inflammation and cancer: back to Virchow? Lancet 357, 539–545 (2001).
Leaf, C. Why we are losing the war on cancer: and how we can win it. Fortune 77–92 (9 Mar 2004).
Acknowledgements
The author thanks the many disease advocacy organizations for their hard work, and acknowledges the bold policy makers who put health above politics.
Author information
Authors and Affiliations
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Terry, S. Accelerate medical breakthroughs by ending disease earmarks. Nat Rev Genet 11, 310–311 (2010). https://doi.org/10.1038/nrg2782
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrg2782